$ARDX @ardelyx CEO didn’t issue a much needed PR on course case or respond to Jeffries Ding 🛎️ BS. So I will: WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today confirmed that the United States Court of Appeals for the District of Columbia Circuit has affirmed the dismissal of the company’s lawsuit regarding the classification of XPHOZAH® (tenapanor) for inclusion in the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) bundle. The company also noted recent analyst commentary regarding potential near-term variability in quarterly sales of IBSRELA®. “We are disappointed
View on X ↗